The impact of patient self-monitoring via electronic medication monitor and mobile app plus remote clinician feedback on adherence to inhaled corticosteroids: a …

GS Mosnaim, DA Stempel, C Gonzalez… - The Journal of Allergy …, 2021 - Elsevier
GS Mosnaim, DA Stempel, C Gonzalez, B Adams, N BenIsrael-Olive, R Gondalia, L Kaye
The Journal of Allergy and Clinical Immunology: In Practice, 2021Elsevier
Background Poor adherence to inhaled corticosteroids (ICSs) and overuse of short-acting
beta 2-agonists (SABAs) are associated with increased asthma morbidity. Objective To
assess whether patient self-monitoring via electronic medication monitoring and smartphone
application plus remote clinician feedback influences ICS and SABA use. Methods Adults
with uncontrolled asthma and prescribed ICS and SABA were enrolled in this 14-week
study. Inhalers were fitted with electronic medication monitoring to track real-time usage …
Background
Poor adherence to inhaled corticosteroids (ICSs) and overuse of short-acting beta2-agonists (SABAs) are associated with increased asthma morbidity.
Objective
To assess whether patient self-monitoring via electronic medication monitoring and smartphone application plus remote clinician feedback influences ICS and SABA use.
Methods
Adults with uncontrolled asthma and prescribed ICS and SABA were enrolled in this 14-week study. Inhalers were fitted with electronic medication monitoring to track real-time usage. After a 14-day baseline, participants were randomly assigned to the treatment group where they received reminders and feedback on ICS and SABA use via a smartphone application and clinician phone calls, or control group without feedback. Linear mixed models compared the baseline percentage of SABA-free days and ICS adherence to the last 14 study days.
Results
Participants (n = 100) had a mean age of 48.5 years, 80% were female, 68% white, and 80% privately insured. The percentage of SABA-free days increased significantly in the treatment group (19%; 95% CI, 12 to 26; P < .01) and nonsignificantly in the control group (6%, 95% CI, −3 to 16; P = .18), representing a 13% (95% CI, 1-26; P = .04) difference. ICS adherence changed minimally in the treatment group (−2%; 95% CI, −7 to 3; P = .40), but decreased significantly (−17%; 95% CI, −26 to −8; P < .01) in the control group, representing a 15% (95% CI, 4 to 25; P < .01) difference.
Conclusions
Patient self-monitoring via a digital platform plus remote clinician feedback maintained high baseline ICS adherence and decreased SABA use.
Elsevier
以上显示的是最相近的搜索结果。 查看全部搜索结果